Vaxcyte (PCVX) Common Equity (2019 - 2026)
Vaxcyte (PCVX) recorded Common Equity of $2.49 billion in Q3 2026, down 14.0% from $2.89 billion a year earlier and down 9.7% from the prior quarter.
Powered by 
Analysis
Vaxcyte (PCVX) Common Equity (2019 - 2026) Analysis & Trends
At the end of FY2025, Vaxcyte reported Common Equity of $2.69 billion, down 18.8% from FY2024.
- Annual Common Equity has a five-year compound annual growth rate of 50.7% (FY2020 to FY2025).
- Across earlier years, Common Equity came in at $3.31 billion in FY2024 (+166.5%), $1.24 billion in FY2023 (+30.1%), $953.61 million in FY2022 (+235.8%) and $284.02 million in FY2021 (-17.9%).
- The Q3 2026 figure is the lowest quarterly Common Equity since Q2 2024.
- On a year-over-year basis, Common Equity has declined for five consecutive quarters, with growth averaging 27.2% over the last eight quarters.
- Peak year-over-year performance for Common Equity in the last five years was growth of 291.1% in Q2 2023, against a decline of 18.8% in Q4 2025 at the low end.
- Per Business Quant, the preceding three quarters came in at $2.76 billion (Q2 2026), $3 billion (Q1 2026) and $2.69 billion (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 40.27 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 81.53 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | -4.58 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 44.95 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 51.81 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 14.35 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 13.04 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 89.30 Bn |
| 10 | Vaxcyte | 9.91 Bn | 3.83 Bn | - | 2.49 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 2.49 Bn |
| Jun 30, 2026 | 2.76 Bn |
| Mar 31, 2026 | 3.00 Bn |
| Dec 31, 2025 | 2.69 Bn |
| Sep 30, 2025 | 2.89 Bn |
| Jun 30, 2025 | 3.07 Bn |
| Mar 31, 2025 | 3.20 Bn |
| Dec 31, 2024 | 3.31 Bn |
| Sep 30, 2024 | 3.42 Bn |
| Jun 30, 2024 | 1.99 Bn |
| Mar 31, 2024 | 1.98 Bn |
| Dec 31, 2023 | 1.24 Bn |
| Sep 30, 2023 | 1.40 Bn |
| Jun 30, 2023 | 1.43 Bn |
| Mar 31, 2023 | 944.77 Mn |
| Dec 31, 2022 | 953.61 Mn |
| Sep 30, 2022 | 359.31 Mn |
| Jun 30, 2022 | 366.50 Mn |
| Mar 31, 2022 | 359.54 Mn |
| Dec 31, 2021 | 284.02 Mn |
API Access
Vaxcyte Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=PCVX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "PCVX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=PCVX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();